Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 37Neoplasms 30Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Neoplasm Metastasis 5Rectal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Glioma 3Colonic Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Solid Tumors 1Skin Neoplasms 1

Interventions

adavosertib 2veliparib 1trametinib 1pamiparib 1cabozantinib 1Temozolomide 1Everolimus 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignant Solid Neoplasm × trametinib × Clear all
NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

National Cancer Institute (NCI)

Phase 2 Completed
208 enrolled 27 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡